Results

1–9 of 9 results for rho

Neighborhood-Level Characteristics Associated With Delay in Surgery and Loss to Follow-up in Tractional Retinal Detachment Due to Proliferative Diabetic Retinopathy
Sally S Ong, MD
Annual Meeting Talks
2025
From Bench to Bedside: Investigating the Use of Netarsudil as a Novel Therapeutic Approach for PVR
Leo A. Kim, MD, PhD
Annual Meeting Talks
2025
A Novel Modifier Gene Therapy for Retinitis Pigmentosa: 2-Year Results of a Phase 1/2, Multicenter, Dose-Escalation Study of Subretinal OCU400
Syed Shah, MD
Annual Meeting Talks
2025
Update on Faricimab for DME: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2025
Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy
Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS
Annual Meeting Talks
2024
One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
Annual Meeting Talks
2024
Individual and Neighborhood-Level Socioeconomic Characteristics Associated With Presenting Visual Acuity and Foveal Status in Rhegmatogenous Retinal Detachment
Sally S Ong, MD
Annual Meeting Talks
2024
Rho-kinase Inhibition on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy
Leo A. Kim, MD, PhD
Annual Meeting Talks
2021
Rho Kinase Inhibition Reduces Photoreceptor Damage After Retinal Detachment: Possible Implications for Gene and Cell Therapy
Marco A. Zarbin, MD, PhD
Updates from the Field
2021